Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14639057 | 0.89 | TDO2 (0.38) | TDO2GAAPOLBLMNASMN1; SMN2 | |
| SCHEMBL243599 | 0.85 | NR1I2 (0.34) | NR1I2 | |
| SCHEMBL29773086 | 0.80 | CYP1A2 (0.36) | L3MBTL1NR1I2 | |
| SCHEMBL242040 | 0.80 | CYP1A2 (0.36) | L3MBTL1NR1I2 | |
| SCHEMBL3286259 | 0.80 | ALDH1A1 (0.35) | L3MBTL1POLBNR1I2 | |
| SCHEMBL14639126 | 0.78 | ALDH1A1 (0.40) | TDO2L3MBTL1LMNAMAPT | |
| SCHEMBL14654518 | 0.78 | PDE4A (0.39) | GAAPOLBMAPT | |
| SCHEMBL19157031 | 0.78 | NR1I2 (0.31) | NR1I2 | |
| SCHEMBL12432021 | 0.74 | NR1I2 (0.30) | NR1I2 | |
| SCHEMBL21802398 | 0.74 | RXRA (0.41) | MEN1GAAKMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709104-B2 | Aminoanthryl derivative-substituted pyrene compound and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20060115678-A1 | Aminoanthryl derivative-substituted pyrene compound and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115678-A1 | Aminoanthryl derivative-substituted pyrene compound and organic light-emitting device | ALAD, PAH, PPOX | TDO2 28/4885MEN1 3182/4885GAA 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.